aTyr Pharma Inc (LIFE)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:aTyr Pharma Inc (LIFE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011839
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
aTyr Pharma Inc (aTyr Pharma) is a biotherapeutics company that discovers and develops physiocrine-based therapies. The company’s resolaris is a potential intravenous protein therapeutic for the treatment of rare myopathies with an immune component. It offers phyisiocrine, which is a class of endogenous human proteins from amino acyl tRNA synthetases that function as extracellular signaling molecules in different physiologic settings. aTyr Pharma develops drugs for cancer, neurodegenerative diseases, inflammation, and metabolic disorders. The company collaborates with research institutions for its research and development activities. It has presence in the US and Hong Kong. aTyr Pharma is headquartered in San Diego, California, the US.

aTyr Pharma Inc (LIFE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
aTyr Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
aTyr Pharma Raises USD76 Million in Series E Financing 11
aTyr Pharma Raises US$49 Million In Series D Financing 13
Partnerships 14
Pangu BioPharma Renews Agreement with Hong Kong University of Science and Technology 14
aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 15
Equity Offering 16
aTyr Pharma Plans to Raise up to USD72 Million in Public Offering of Shares 16
aTyr Pharma Raises USD45.8 Million in Private Placement of Shares, Preferred Shares and Warrants 17
aTyr Pharma to Raise up to USD20 Million in Public Offering of Shares 19
aTyr Pharma Raises USD86.3 Million in IPO of Shares 20
aTyr Pharma Inc – Key Competitors 22
aTyr Pharma Inc – Key Employees 23
aTyr Pharma Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Nov 14, 2017: aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update 25
Aug 14, 2017: aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline 27
May 11, 2017: aTyr Pharma Announces First Quarter 2017 Operating Results 29
Mar 16, 2017: aTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating Results 31
Nov 14, 2016: aTyr Pharma Announces Third Quarter 2016 Operating Results 33
Aug 10, 2016: aTyr Pharma Announces Second Quarter 2016 Operating Results 35
May 11, 2016: aTyr Pharma Announces First Quarter 2016 Operating Results 37
Mar 30, 2016: aTyr Pharma Announces Fourth Quarter 2015 Operating Results 38
Corporate Communications 39
Nov 01, 2017: aTyr Pharma Announces Leadership Transition 39
Apr 10, 2017: aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors 40
Apr 03, 2017: aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors 41
Mar 30, 2016: aTyr Pharma Appoints Sanjay Shukla, MD, MS, as Chief Medical Officer 42
Jan 06, 2016: aTyr Pharma Appoints Sanuj Ravindran, M.D., as Chief Business Officer 43
Product News 44
05/15/2017: aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar 44
Other Significant Developments 45
Jan 11, 2016: aTyr Provides Corporate Update And Outlook For 2016 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
aTyr Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
aTyr Pharma Inc, Deals By Therapy Area, 2011 to YTD 2017 9
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
aTyr Pharma Raises USD76 Million in Series E Financing 11
aTyr Pharma Raises US$49 Million In Series D Financing 13
Pangu BioPharma Renews Agreement with Hong Kong University of Science and Technology 14
aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 15
aTyr Pharma Plans to Raise up to USD72 Million in Public Offering of Shares 16
aTyr Pharma Raises USD45.8 Million in Private Placement of Shares, Preferred Shares and Warrants 17
aTyr Pharma to Raise up to USD20 Million in Public Offering of Shares 19
aTyr Pharma Raises USD86.3 Million in IPO of Shares 20
aTyr Pharma Inc, Key Competitors 22
aTyr Pharma Inc, Key Employees 23
aTyr Pharma Inc, Subsidiaries 24

★海外企業調査レポート[aTyr Pharma Inc (LIFE)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lantronix, Inc. (LTRX):企業の財務・戦略的SWOT分析
    Lantronix, Inc. (LTRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Hill International, Inc. (HIL):企業の財務・戦略的SWOT分析
    Hill International, Inc. (HIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • NeuroGenetic Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary NeuroGenetic Pharmaceuticals Inc (NeuroGenetic Pharmaceuticals) is a pharmaceutical company that develops drugs for Alzheimer’s diseases. The company develops products with its gamma-secretase modulators technology. It applies multiple lead compounds for the treatment of neurodegenerative co …
  • Real Matters Inc (REAL):企業の財務・戦略的SWOT分析
    Real Matters Inc (REAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • WAVE Life Sciences Ltd (WVE):企業の財務・戦略的SWOT分析
    Summary Wave Life Sciences Ltd (Wave Life Sciences) formerly WAVE Life Sciences Pte Ltd, discovers, develops and commercializes medicines for genetic diseases. The company's pipeline comprises an mRNA transcript candidates: WVE-120101 and WVE-120102 for Huntington's disease; ATXN3 gene candidate for …
  • MeVis Medical Solutions AG (M3V)-医療機器分野:企業M&A・提携分析
    Summary MeVis Medical Solutions AG (MMS AG) is a medical technology company. It develops and offers medical imaging solutions for digital computer-aided medical imaging. The software solutions are used in screening, diagnostics, therapy and intervention planning for breast, lung, colon, and prostate …
  • Qube Holdings Ltd:戦略・SWOT・企業財務分析
    Qube Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Qube Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Korea Electric Power Corporation:企業の戦略・SWOT・財務情報
    Korea Electric Power Corporation - Strategy, SWOT and Corporate Finance Report Summary Korea Electric Power Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Osaka Gas Co Ltd (9532):石油・ガス:M&Aディール及び事業提携情報
    Summary Osaka Gas Co Ltd (OGCL) supplies natural gas to its customers in Kansai region, besides offering LPG, electricity and other energy-related products and services through affiliated enterprises. Its operations consist of domestic energy, environmental and non-energy, and international energy b …
  • Minoryx Therapeutics sl:製薬・医療:M&Aディール及び事業提携情報
    Summary Minoryx Therapeutics sl (Minoryx) is a clinical stage biotechnology company that develops treatments for life threatening rare diseases. The company offers discovery, preclinical research, development and clinical trial programs. It develops ALD-MIN, morquio B and PCT drugs used for lysosoma …
  • Traverse Energy Ltd (TVL):企業の財務・戦略的SWOT分析
    Summary Traverse Energy Ltd (Traverse Energy), formerly Firstland Energy Ltd is an oil and gas company that explores, produces, and develops petroleum and natural gas assets. The company's products include crude oil, natural gas, petroleum products, and associated liquids, among others. It explores …
  • Europaeische Reiseversicherung AG:企業の戦略・SWOT・財務情報
    Europaeische Reiseversicherung AG - Strategy, SWOT and Corporate Finance Report Summary Europaeische Reiseversicherung AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Total Energy Services Inc (TOT):石油・ガス:M&Aディール及び事業提携情報
    Summary Total Energy Services Inc (Total Energy) is an energy services company. It offers contract drilling services and rental and transportation services for equipment utilized in drilling, completion and production activities in oil and gas wells. The company also provides fabrication, sale, rent …
  • Saneca Pharmaceuticals as:製薬・医療:M&Aディール及び事業提携情報
    Summary Saneca Pharmaceuticals as (Saneca Pharma) is a contract development and manufacturing organization that develops and manufactures active pharmaceutical ingredients and finished dosage forms. The organization provides products such as API's; 2-aminotridecane adipate, atorvastatin calcium crys …
  • EMIS Group plc (EMIS):企業の財務・戦略的SWOT分析
    Summary EMIS Group Plc (EMIS), formerly Egton Medical Information Systems Ltd, is a provider of information technology and related services. The company provides electronic patient record systems and software solutions such as EMIS web, used for clinical services; EMIS IQ for data extraction; and sy …
  • Nuo Therapeutics Inc (AURX):企業の財務・戦略的SWOT分析
    Nuo Therapeutics Inc (AURX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Banco Comercial Portugues S.A:企業のM&A・事業提携・投資動向
    Banco Comercial Portugues S.A - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Banco Comercial Portugues S.A Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Shanghai Shyndec Pharmaceutical Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Shanghai Shyndec Pharmaceutical Co Ltd (Shanghai Shyndec) a subsidiary of China National Pharmaceutical Group Corp, is a pharmaceutical company which focuses on the production and sale of active pharmaceutical ingredients (API’s), oral preparations and finished drugs. Its product portfolio i …
  • Del Taco Holdings, Inc.:企業の戦略・SWOT・財務情報
    Del Taco Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Del Taco Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Lay Hong Berhad (LAYHONG):企業の財務・戦略的SWOT分析
    Lay Hong Berhad (LAYHONG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆